KR101671341B1 - 다이아미노피리미딘 유도체 및 그의 제조방법 - Google Patents

다이아미노피리미딘 유도체 및 그의 제조방법 Download PDF

Info

Publication number
KR101671341B1
KR101671341B1 KR1020120018926A KR20120018926A KR101671341B1 KR 101671341 B1 KR101671341 B1 KR 101671341B1 KR 1020120018926 A KR1020120018926 A KR 1020120018926A KR 20120018926 A KR20120018926 A KR 20120018926A KR 101671341 B1 KR101671341 B1 KR 101671341B1
Authority
KR
South Korea
Prior art keywords
piperidin
propylpyrimidin
group
amino
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020120018926A
Other languages
English (en)
Korean (ko)
Other versions
KR20120098483A (ko
Inventor
이현주
김동훈
김태균
윤영애
심재영
차명훈
정은정
안경규
이태오
Original Assignee
주식회사유한양행
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사유한양행 filed Critical 주식회사유한양행
Publication of KR20120098483A publication Critical patent/KR20120098483A/ko
Application granted granted Critical
Publication of KR101671341B1 publication Critical patent/KR101671341B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020120018926A 2011-02-25 2012-02-24 다이아미노피리미딘 유도체 및 그의 제조방법 Active KR101671341B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110016981 2011-02-25
KR1020110016981 2011-02-25

Publications (2)

Publication Number Publication Date
KR20120098483A KR20120098483A (ko) 2012-09-05
KR101671341B1 true KR101671341B1 (ko) 2016-11-01

Family

ID=46721361

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020120018933A Active KR101671348B1 (ko) 2011-02-25 2012-02-24 다이아미노피리미딘 유도체 및 그의 제조방법
KR1020120018926A Active KR101671341B1 (ko) 2011-02-25 2012-02-24 다이아미노피리미딘 유도체 및 그의 제조방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020120018933A Active KR101671348B1 (ko) 2011-02-25 2012-02-24 다이아미노피리미딘 유도체 및 그의 제조방법

Country Status (17)

Country Link
US (4) US9890138B2 (enExample)
EP (2) EP2678331B1 (enExample)
JP (2) JP5980236B2 (enExample)
KR (2) KR101671348B1 (enExample)
CN (2) CN103391935B (enExample)
AU (2) AU2012221927B2 (enExample)
BR (2) BR112013020641B1 (enExample)
CA (2) CA2827072C (enExample)
DK (1) DK2678332T3 (enExample)
ES (2) ES2579830T3 (enExample)
HU (1) HUE029988T2 (enExample)
IN (1) IN2013MN01519A (enExample)
MX (2) MX337477B (enExample)
PL (2) PL2678332T3 (enExample)
PT (1) PT2678332T (enExample)
RU (1) RU2587493C2 (enExample)
WO (2) WO2012115480A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2678332T3 (pl) * 2011-02-25 2016-12-30 Pochodne diaminopirymidyny i sposoby ich wytwarzania
EP2922828B1 (en) 2012-11-21 2020-07-08 PTC Therapeutics, Inc. 4,6-diamino-pyrimidine derivatives as bmi-1 inhibitors for treating cancer
KR101657616B1 (ko) * 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
TWI692477B (zh) * 2013-08-30 2020-05-01 美商Ptc治療公司 經取代嘧啶bmi-1抑制劑
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CN104003944B (zh) * 2014-05-29 2016-08-24 西北师范大学 一种嘧菌胺的制备方法
HRP20250213T1 (hr) 2014-10-13 2025-04-25 Yuhan Corporation Spojevi i pripravci za modulaciju aktivnosti egfr mutantne kinaze
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN105646321A (zh) * 2016-01-07 2016-06-08 中国药科大学 (s)-3-羟基吡咯烷盐酸盐的制备方法
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
KR102441327B1 (ko) * 2018-05-18 2022-09-07 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 산부가염의 신규의 제조방법
US12023335B2 (en) 2018-08-17 2024-07-02 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
CA3122182A1 (en) * 2018-12-18 2020-06-25 Astrazeneca Ab Pharmaceutical process and intermediates
CN110317176A (zh) * 2019-07-04 2019-10-11 沈阳药科大学 2-氨基嘧啶类化合物及其用途
KR20220006776A (ko) * 2020-07-09 2022-01-18 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법
WO2025104079A1 (en) * 2023-11-17 2025-05-22 Helmholtz-Zentrum für Infektionsforschung GmbH Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1902037B1 (de) 2005-07-01 2009-09-02 Boehringer Ingelheim International GmbH 2,4-diamino-pyrimidine als aurora inhibitoren

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4870074A (en) 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
GB9005014D0 (en) 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
NZ274978A (en) * 1993-10-12 1998-04-27 Du Pont Merck Pharma 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
IL112024A (en) * 1993-12-21 1999-07-14 Novo Nordisk As Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
JP2896532B2 (ja) * 1994-08-13 1999-05-31 ユーハン コーポレーション 新規なピリミジン誘導体およびその製造方法
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
IN188411B (enExample) * 1997-03-27 2002-09-21 Yuhan Corp
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
WO2005011758A2 (en) * 2003-07-25 2005-02-10 Ciba Specialty Chemicals Holding Inc. Use of substituted 2,4-bis (alkylamino) pyrimidines or -quinazolines as antimicrobials
JP2007507425A (ja) * 2003-08-29 2007-03-29 ダイノゲン ファーマシューティカルズ,インコーポレイテッド 胃腸管運動障害を処置するために有用な組成物
US20060057972A1 (en) 2004-09-14 2006-03-16 Wikel Harold L Adapter for a modular wireless communication device
US20060128726A1 (en) 2004-11-24 2006-06-15 Xuebao Wang Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations
ES2523459T3 (es) 2005-02-25 2014-11-26 Raqualia Pharma Inc Derivados de benzisoxazol
WO2007062417A1 (en) * 2005-11-28 2007-05-31 Kalypsys, Inc. Methods of preparing 2-imidazol-1-yl-4-methyl-6-pyrrolidin-2-yl-pyrimidine and 4-(1-alkylpyrrolidin-2-yl)-2-(1h-imidazol-1-yl)-6-methylpyrimidine derivatives
WO2007114323A1 (ja) * 2006-04-04 2007-10-11 Taisho Pharmaceutical Co., Ltd. アミノピロリジン化合物
CA2648170A1 (en) 2006-04-10 2007-10-18 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
CN101952275B (zh) * 2008-02-22 2014-06-18 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr 억제제 및 질환 치료방법
PL2678332T3 (pl) * 2011-02-25 2016-12-30 Pochodne diaminopirymidyny i sposoby ich wytwarzania

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1902037B1 (de) 2005-07-01 2009-09-02 Boehringer Ingelheim International GmbH 2,4-diamino-pyrimidine als aurora inhibitoren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem. 1999, 42, 805-818

Also Published As

Publication number Publication date
BR112013019942A2 (pt) 2018-08-14
KR20120098484A (ko) 2012-09-05
BR112013020641A2 (pt) 2016-10-18
PL2678331T3 (pl) 2016-12-30
US20180072705A1 (en) 2018-03-15
WO2012115480A3 (en) 2012-10-18
US10227330B2 (en) 2019-03-12
EP2678331A4 (en) 2014-07-30
KR20120098483A (ko) 2012-09-05
HUE029988T2 (en) 2017-04-28
US20130338179A1 (en) 2013-12-19
EP2678331A2 (en) 2014-01-01
CA2827072C (en) 2019-01-08
ES2587304T3 (es) 2016-10-21
BR112013020641B1 (pt) 2021-11-03
JP2014506591A (ja) 2014-03-17
JP5890436B2 (ja) 2016-03-22
EP2678331B1 (en) 2016-04-27
CN103391935A (zh) 2013-11-13
PT2678332T (pt) 2016-08-22
EP2678332A2 (en) 2014-01-01
RU2013142188A (ru) 2015-03-27
EP2678332B1 (en) 2016-05-18
WO2012115478A3 (en) 2012-10-18
US10640490B2 (en) 2020-05-05
HK1188214A1 (zh) 2014-04-25
US20130331377A1 (en) 2013-12-12
CN103402997B (zh) 2015-08-26
MX2013009549A (es) 2013-09-06
US20150274700A2 (en) 2015-10-01
BR112013019942B1 (pt) 2022-01-11
WO2012115478A2 (en) 2012-08-30
AU2012221927B2 (en) 2016-04-28
CA2827030A1 (en) 2012-08-30
AU2012221925B2 (en) 2016-05-05
EP2678332A4 (en) 2014-07-23
MX2013009627A (es) 2014-02-17
MX336155B (es) 2016-01-07
PL2678332T3 (pl) 2016-12-30
CN103402997A (zh) 2013-11-20
MX337477B (es) 2016-03-07
US20180111918A1 (en) 2018-04-26
ES2579830T3 (es) 2016-08-17
WO2012115480A2 (en) 2012-08-30
US9850227B2 (en) 2017-12-26
IN2013MN01519A (enExample) 2015-06-12
HK1188215A1 (en) 2014-04-25
JP5980236B2 (ja) 2016-08-31
DK2678332T3 (en) 2016-08-15
KR101671348B1 (ko) 2016-11-01
CA2827072A1 (en) 2012-08-30
US9890138B2 (en) 2018-02-13
RU2013142187A (ru) 2015-03-27
CA2827030C (en) 2019-01-08
JP2014506592A (ja) 2014-03-17
CN103391935B (zh) 2015-12-23
RU2587493C2 (ru) 2016-06-20

Similar Documents

Publication Publication Date Title
KR101671341B1 (ko) 다이아미노피리미딘 유도체 및 그의 제조방법
KR101985050B1 (ko) 피라진카르복사미드 화합물
JP5578785B2 (ja) イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法
JP5335426B2 (ja) ジアリールアミン含有化合物および組成物、ならびにc−kit受容体のモジュレーターとしてのそれらの使用
CN1093858C (zh) 用于治疗、特别是治疗良性前列腺增生的喹啉和喹唑啉化合物
US20110021495A1 (en) Quinazoles useful as modulators of ion channels
EA018046B1 (ru) Сульфониламидные производные в качестве антагонистов брадикининовых рецепторов, их получение и фармацевтическая композиция, их содержащая
MXPA04007502A (es) Derivados de quinolina como antagonistas de neuropeptido y (npy).
AU2003255644B2 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
AU2008240804A1 (en) Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists
CN1784391B (zh) 可用作离子通道调控剂的喹唑啉
RU2587981C2 (ru) Производные диаминопиримидина и способы их получения
HK1188214B (en) Diaminopyrimidine derivatives and processes for the preparation thereof
KR101657616B1 (ko) 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
RU2800278C2 (ru) Соединения
HK1188215B (en) Diaminopyrimidine derivatives and processes for the preparation thereof
JPWO1999055674A1 (ja) 1−[(1−置換−4−ピペリジニル)メチル]−4−ピペリジン誘導体、その製造方法、それを含有する医薬組成物および該化合物の中間体
HK1134927A (en) Derivatives of ureas of piperidine or pyrrolidine, their preparation and their therapeutical use

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190114

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20200213

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10